At the ASCO-SITC Clinical Immuno-Oncology Symposium of 2019, it was shown that in a Phase I a/b trial, the efficacy of LY3321367, an anti-TIM-3 mAb, in patients with NSCLC varied depending on the anti-PD-1/L1 efficacy; that is, the efficacy in anti-PD-1/L1 refractory patients (N = 23, ORR: 0%, DCR: 35%, PFS: 1.9 months) was compared to that in anti-PD-1/L1 responders (N = 14, ORR: 7%, DCR: 50%, PFS: 7.3 months). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.